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Introduction: The coronavirus disease 2019 (COVID-19) vaccination generates protective immunity against SARSCoV-2 infection. There is no clear evidence of COVID-19 vaccine-induced menstrual irregularities.
Objective: To identify potential menstrual irregularities following COVID-19 vaccine among females.
Methods: A worldwide cross-sectional survey study was conducted from June 10, 2021, to July 10, 2021 using
online mediums. The survey consisted of 15 questions divided into baseline characteristics, vaccination status
and dosage, menstruation and relate factors, and thoughts and knowledge about menstrual irregularities. Nonprobability convenience sampling method was used including 510 responses. The results were tabulated, with
bivariate analysis and chi-square test results. The sensitivity and specificity test of factors associated to knowl
edge about menstrual irregularities post COVID-19 vaccination were analyzed by receiver operating character
istic analysis.
Results: The associations between healthcare worker (HCW) status and perceptions (χ2 = 10.422; p = 0.064), and
knowledge about menstrual irregularities post-vaccination (χ2 = 1.966; p = 0.161) were found. Vaccinated
compared to non-vaccinated women had a higher risk of change in inter-cycle length between periods
(OR = 3.172; 95% CI = 0.470–21.431). Of 314 HCW vs. 196 non-HCW, 60 (19.1%) vs. 28 (14.3%) were
knowledgeable about menstrual irregularities (OR = 1.338, 95% CI = 0.886–2.019 vs. OR = 0.944; 95%
CI = 0.873–1.021). On asking the HCW vs. non-HCW about perceptions of COVID-19 vaccine-induced menstrual
irregularities, 24 (7.6%) vs. 9 (4.6%) agreed, 139 (44.3%) vs. 67 (34.2%) disagreed, and 151 (48.1%) vs. 120
(61.2%) did not know or chose not applicable.
Conclusion: There is a gap in the current understanding of menstrual irregularities, even if temporary, following
COVID-19 vaccination that requires further exploration. Misinformation may also be the culprit for the observed
proportion of women that noticed changes in their menstrual periods after COVID-19 vaccination.

1. Introduction
The COVID-19 vaccination has been observed to generate protective
immunity against SARS-CoV-2 infection with anecdotal evidence of
menstrual irregularities possibly due to physical reaction to the vaccine.
There is no clear evidence of COVID-19 vaccine-induced menstrual

irregularities. Additionally, there are scientific associations of sexspecific responses to influenza vaccination with stronger humoral and
cellular responses among women [1,2]. Declined ovarian reserve was
observed in women of reproductive age with COVID-19 infection as
reported by Ding and colleagues [3]. Our survey aims to identify po
tential side effects of COVID-19 vaccinations concerning menstrual
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irregularities among women across the globe. With this survey, we aim
to identify a potentially relevant side effect for women of reproductive
age trying to conceive, postmenopausal women who may consider
breakthrough bleeding as a sign of serious disease, as well as trans
women. We also explore plausible mechanisms that may result in
menstrual irregularities following COVID-19 vaccine.

3. Results
With 590 all-time clicks, 510 respondents complete the survey, giv
ing rise to a response rate of 86.3%. On using the entire sample
(N = 510), no association was found between the HCW status and
thoughts about menstrual irregularities (χ2) = 10.422, p = 0.064.
Similarly, we found that the HCW status and knowledge about men
strual irregularities following COVID-19 vaccination had no associations
as well (χ2) = 1.966, p = 0.161.
To omit confounders, the chi-square test of independence was re-run
by include 1) Vaccinated, 2) With regular menstrual periods, 3) who did
not take any medications (i.e., OCPs or NSAIDS) that could impact pe
riods in the last 12 months before getting vaccinated, 4) who had at least
one or more menstrual periods post-vaccination; N = 340. The re-run
yielded the following associations between vaccinated individuals
with regular periods, who did not take any medications that could
impact periods in the last one year, and who had at least one period postvaccination to thoughts about menstrual irregularities (χ2) = 7.418,
p = 0.191 and knowledge about menstrual irregularities (χ2) = 3.137,
p = 0.077.
Of the 314 HCWs, 60 (19.1%) heard of menstrual irregularities
following COVID-19 vaccination from friends, family or colleagues
(OR = 1.338; 95 CI = 0.886–2.019). On the other hand, 28 (14.3%) of
the general population (N = 196) heard of the irregularities from
friends, family, or colleagues (OR = 0.944; 95% CI = 0.873–1.021). On
asking the HCWs vs. the general population whether menstrual irregu
larities may be caused by the vaccine, 9 (2.9%) vs. 4 (2%) strongly
agreed, 15 (4.8%) vs. 5 (2.6%) agreed, 82 (26.1%) vs. 69 (35.2%) did
not know, 77 (24.5%) vs. 43 (21.9%) disagreed, 62 (19.7%) vs. 24
(12.2%) strongly disagreed, and 69 (22%) vs. 51 (26%) chose not
applicable. Among all participants (N = 510), vaccinated individuals
presented with a higher risk of change in length of the cycle between
periods (OR = 3.172; 95% CI = 0.470–21.431), as opposed to the nonvaccinated respondents (OR = 0.864; 95% CI = 0.762–0.980) (see
Table 1).
Figs. 1 and 2 showcases findings from the sensitivity and specificity
analysis using the ROC curve for all questions about the knowledge of
menstrual irregularities due to COVID-19 vaccination. We found that the
country of origin of the participant (AUC = 0.602, 95%
CI = 0.538–0.666) had the strongest association to knowledge about
menstrual irregularities, with vaccination status (AUC = 0.5, 95%
CI = 0.434–0.567) being an acceptable model (Fig. 1).
The strongest associations to knowledge in the questionnaire were
found with the vaccine dosage (AUC = 0.519, 95% CI = 0.455–0.585),
regularity of periods in the previous 12 months (AUC = 0.54, 95%
CI = 0.474–0.605), and age at first period (AUC = 0.508, 95%
CI = 0.44–0.571) (Fig. 2).

2. Methods
A population-based cross-sectional study was conducted by means of
an electronic survey distributed to healthcare workers and the general
population members, who were female, across the world. Using online
media platforms, the survey was distributed from June 10, 2021, to July
10, 2021. The Institutional Review Board (Ministerio de Salud Publica)
(Ref No. 024–2020) at Universidad de Especialidades Espíritu Santo,
Ecuador approved the study before the distribution of the survey. This
study was additionally registered with Research Registry: researchreg
istry7876 [4].
The survey instrument was created to address the study objectives.
This involved wording the questions based on the baseline characteris
tics (2 questions), vaccination status and dosage obtained (2 questions),
menstruation and related factors (11 questions), thoughts and knowl
edge about menstrual irregularities (2 questions). Participants were
asked their HCW status and whether they thought menstrual irregular
ities could have been caused due to the COVID-19 vaccine with six
answer choices: strongly agree, agree, don’t know, disagree, strongly
disagree, and not applicable. They were also questioned concerning
their knowledge about menstrual irregularities following COVID-19
vaccination, with two answer choices: yes, or no.
The target population was selected based on non-probability con
venience sampling, comprising females worldwide who wished to
voluntarily partake in the study. Sample size was calculated with
OpenEpi software to be 384 using the estimate of population size to be
1,000,000 persons due to lack of exact number of population size being
addressed. The sample size was calculated using the following formula:
[DEFF*Np(1-p)]/[(d2/Z21-α/2*(N-1) +p*(1-p)]. The predicted hy
pothesis of outcome factor was estimated as 50% as there are no clear
studies in the subject. The confidence interval was 95%, and accepted
margin of error was 5%. All participants were informed of the survey
details using a consent form to participate on beginning the survey,
which was approved by the ethical review committee. The aim of the
study along with the consent form was attached to the questionnaire.
Those who did not wish to participate and responses that were incom
plete were excluded. The STROCSS 2021 checklist is appended in the
supplementary materials [5].
Questionnaire responses were analyzed using Statistical Package for
the Social Sciences (SPSS v25). Descriptive statistics were summarized
for baseline characteristics, vaccination and dosage, and factors associ
ated to menstrual irregularities, and thoughts and knowledge about
menstrual irregularities. Bivariate analyses were used to compare the
characteristics of responses to knowledge about menstrual irregularities.
Furthermore, the chi-square test of independence was conducted to
determine associations between HCW status, perceptions, and knowl
edge of COVID-19 vaccination. A sensitivity analysis was conducted to
omit confounders, which was presented separately in the results. This
sub analysis only comprised of 340 vaccinated women with regular
menstrual periods, who did not take any medications (i.e., OCPs or
NSAIDS) that could impact periods in the last 12 months before getting
vaccinated, and who had at least one or more menstrual periods postvaccination.
The receiver operating characteristic (ROC) analysis was conducted
to assess the sensitivity and specificity of all variables associated to
knowledge about menstrual irregularities. Because of the anticipated
biases subjected to participants in the questionnaire responses, the AUC
value of over 0.5 was considered to be a good model.

4. Discussion
So far, there has been no link to changes in ovarian reserve following
IVF among vaccinated women [6]. Menstrual changes may impact the
ovulatory status of women who have not received stimulatory cycles.
Potential ovulatory changes induced by vaccination are relevant for
women of reproductive age who are trying to conceive [7]. For post
menopausal women and transwomen, the breakthrough bleeding may
also represent signs of cancer [8,9]. There is a gap in the current un
derstanding of menstrual irregularities, even if temporary, following
COVID-19 vaccination that requires further exploration. Misinformation
may also be the culprit for the observed proportion of women that
noticed changes in their menstrual periods after COVID-19 vaccination.
As reports of menstrual irregularities increase including breakthrough
bleeding, missed or late periods, and heavy periods, it is important to
consider the biological impact of COVID-19 vaccines.
There is an association between stress (e.g. physical and mental) and
sex hormone fluctuations [10,11]. Observations regarding menstrual
2
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Table 1
Demographics, vaccination status, traits of menstruation, medications, percep
tions, and knowledge about menstrual irregularities due to COVID-19 vaccine.
N (%)
Healthcare worker
Yes
No
Country of residence
India
Pakistan
USA
Bangladesh
Nepal
Canada
Ecuador
Cyprus
UK
Malaysia
UAE
Bolivia
Dominica
Germany
Guyana
Italy
Japan
KSA
Kuwait
Nigeria
Oman
Sint Maarten
Venezuela
Vaccinated
Yes
No
Doses received to complete the
vaccination
Completed after one dose
Completed after two doses
Incomplete after one dose
Age on first period
Age (Mean ± SD)
Periods the last 12 months
My periods have stopped
They have been irregular for a few
months
They have never been regular
Cause of irregular periods before
being vaccinated
Currently breastfeeding
Currently pregnant
Dietary cause
Environmental cause
Exercise
Physiological hormonal changes
On treatment (e.g., hormonal IUD,
contraceptive implants)
Menopause
Polycystic ovary syndrome
Pre-menopause
Stress
Recent weight fluctuation
Not applicable
Usual interval between periods or
the usual interval between periods
before they became irregular or
stopped
Less than 24 days
24–26 days
24–26 days
30–32 days
More than 35 days
Change in the length of cycle
between periods after getting
vaccinated for COVID-19
Yes
No

314 (61.6)
196 (38.4)
195 (38.2)
178 (34.9)
67 (13.1)
18 (3.5)
13 (2.5)
7 (1.4)
6 (1.2)
5 [1]
5 [1]
2 (0.4)
2 (0.4)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
1 (0.2)
493 (96.7)
17 (3.3)

χ2

p-value
(bivariate)

1.966

0.162

22.783

0.001

0.002

0.965

1.923

0.443

49 (9.6)
335 (65.7)
126 (24.7)
13.14 ± 2.768
9 (1.8)
84 (16.5)
417 (81.8)

–

0.585

8.032

0.238

22⋅438

0⋅680

Table 1 (continued )
N (%)
Periods sooner or later after getting
vaccinated
Later
Same
Sooner
Periods after being vaccinated
0
1
2
3
4
5
6
Witnessed heavier or lighter
bleeding during periods after
getting vaccinated
Heavier
Lighter
Same
Bleeding for more or fewer days
after getting vaccinated, as
compared to periods in the last 12
months
Fewer days
More days
Same
Consumed any medications that
could impact periods (e.g., OCPs
or NSAIDs) in the last 12 months
before being vaccinated
Yes
No
Consumed any medications to help
with periods (e.g., OCPs or
NSAIDS) after being vaccinated
Yes
No
Thoughts about menstrual
irregularities possibly caused by
the COVID-19 vaccine
Strongly agree
Agree
Don’t know
Disagree
Strongly disagree
Not applicable
Heard of menstrual irregularities
following the COVID-19
vaccination from friends, family,
or colleagues
Yes
No

4 (0.8)
9 (1.8)
9 (1.8)
7 (1.4)
1 (0.2)
11 (2.2)
31 (6.1)
16 (3.1)
98 (19.2)
2 (0.4)
35 (6.9)
10 [2]
277 (54.3)

45 (8.8)
100 (19.6)
171 (33.5)
142 (27.8)
52 (10.2)

2.037

0.792

66.913

<0.001

92 [18]
366 (71.8)
52 (10.2)
42 (8.2)
175 (34.3)
130 (25.5)
85 (16.7)
50 (9.8)
23 (4.5)
5 [1]

50 (9.8)
74 (14.5)
386 (75.7)

58 (11.4)
36 (7.1)
416 (81.6)

99 (19.4)
411 (80.6)

90 (17.6)
420 (82.4)

13 (2.5)
20 (3.9)
151 (29.6)
120 (23.5)
86 (16.9)
120 (23.5)

χ2

p-value
(bivariate)

40.143

0.024

4.936

0.626

17.365

<0.001

22.922

<0.001

6.981

0.008

0.577

0.449

91.924

<0.001

reference

<0.001

88 (17.3)
422 (82.7)

irregularities have been reported in literature following the HPV vaccine
administration in young women [12]. There have been reports that have
supported and opposed the possibility of associations between HPV
vaccination and premature ovarian failure (POI) [13,14]. Possible un
derlying pathophysiological mechanisms are multifactorial, such as
induced autoimmune responses and adjuvant adverse effects of vaccines
[15]. These reports are relevant for certain COVID-19 vaccines, as
aluminum salts have been used as an adjuvant in their development
[16]. Both COVID-19 vaccines (e.g. Sinopharm) and HPV vaccines
employ aluminum salt, used typically to enhance antigen-specific im
mune responses [17,18]. Not all COVID-19 vaccines contain the toxic
ingredient (aluminum), however, some Chinese COVID-19 vaccines as
well as vaccines used for other diseases do use tiny amounts of
aluminum to boost the immune response [19]. Animal studies have
demonstrated that aluminum may build up in the ovaries, impacting its
integrity, weight, and ability to produce sex hormones. When observed
in female rats, there has a suppression in the concentration of estrogen,
progesterone, FSH, and LH resulting in abnormal development of

93 (18.2)
417 (81.8)
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thrombocytopenia and in rare cases, suggestive of TTS [22]. As efforts
are being made to report vaccine adverse events to reporting systems,
healthcare workers (HCWs) are advised to encourage and inform women
to report these bleeding events or irregularities. From a public health
perspective, these events may be temporary, however, they may indicate
underlying severe adverse events such as TTS associated with a high rate
of fatality.
5. Strengths and limitations
We reported findings of menstrual changes post covid-19 vaccina
tion, of which evidence remains equivocal. In this study, we collected
menstrual data from a large number of women; only the previous 3
months were inquired upon, thus we do not expect recall bias. Previous
menstrual irregularities were also considered as well as baseline char
acteristics to control for confounders. The survey was anonymous which
likely encouraged participants to respond despite the sensitive nature of
the study. The findings of this study are robust due to the large sample
size.
Our study has a few limitations. First, while we included an
acceptable number of participants, we could not distribute paper forms,
leading to reporting bias. Especially during the COVID-19 pandemic,
with many non-peer reviewed scientific data such as media reports being
used as information sources, self-reporting bias in responses may have
positively or negatively tilted our findings. Second, as opposed to lon
gitudinal study designs, cross-sectional survey study designs cannot
account for clinical testing, thereby limiting causality. Third, there was
no long-term follow up and this study presents a snapshot of survey
findings about menstrual irregularities due to COVID-19 vaccine.

Fig. 1. ROC curve for the sensitivity and specificity of knowledge about men
strual irregularities. The curve shows that the country of origin is a generally
good model, with vaccinated individuals being more knowledgeable of men
strual irregularities. Knowledge about menstrual irregularities is the refer
ence line.

follicles in the ovaries [20,21].
It is plausible that vaccine-induced thrombocytopenia is responsible
for heavy menstrual bleeding associated with COVID-19 vaccines [22].
Reports of thrombosis with thrombocytopenia syndrome (TTS)
following COVID-19 vaccination demonstrate thrombocytopenia of
varying degrees, associated with thrombosis in unusual locations [23].
The underlying mechanism that is being considered is autoimmune
heparin-induced thrombocytopenia (aHIT) [24]. Interestingly, TTS is
more frequent in younger women aged 18–49 years [25]. It is plausible
that
menstrual irregularities may be
compounded with

6. Conclusion
To summarize, our findings demonstrate changes in menstrual pat
terns after receiving one or more doses of the COVID-19 vaccine. The
side effect has not been identified so far. This study is the first to explore
menstrual irregularities among women across the globe following
vaccination. It is pertinent to explain to women receiving the

Fig. 2. ROC curve for factors with the strongest association to knowledge about menstrual irregularities. Knowledge about menstrual irregularities is the refer
ence line.
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vaccination for COVID-19 that menstrual irregularities may be expected.
For women who are focusing on conceiving or are post-menopausal,
these menstrual irregularities are necessary to be aware of. Focused
reproductive observatory safety studies are warranted to determine
potentially short- and long-term adverse events of COVID-19 vaccines
among women.

org/10.1016/j.amsu.2022.104220.
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